Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms.
CDK4/6 inhibitors
breast cancer
combination administration
drug resistance
molecular mechanisms
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
01
2021
accepted:
01
02
2021
entrez:
14
6
2021
pubmed:
15
6
2021
medline:
15
6
2021
Statut:
epublish
Résumé
Breast cancer is a common malignant tumor in women, with a highest incidence and mortality among all of the female malignant tumors. Notably, targeted therapy has achieved impressive success in the treatment of breast cancer. As one class of the anti-tumor targeted therapeutics, Cyclin-Dependent Kinases 4/6CDK4/6inhibitors have shown good clinical activity in treating breast cancer. Nevertheless, despite the promising clinical outcomes, intrinsic or acquired resistance to CDK4/6 inhibitors has limited the benefits of this novel target therapy. In the present review, we provide an overview of the currently known molecular mechanisms of resistance to CDK4/6 inhibitors, and discuss the potential strategies to overcoming drug resistance improving the outcomes for breast cancer patients treated with CDK4/6 inhibitors.
Identifiants
pubmed: 34123801
doi: 10.3389/fonc.2021.651541
pmc: PMC8187902
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
651541Informations de copyright
Copyright © 2021 Wang, Li, Wu, Liu, Ren, Li, Bi, Wang and Jia.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Cancer Res. 2017 Aug 15;23(16):4540-4544
pubmed: 28442503
Oncotarget. 2020 Apr 28;11(17):1478-1492
pubmed: 32391118
Ann Oncol. 2018 Jul 1;29(7):1541-1547
pubmed: 29718092
Ann Oncol. 2018 Mar 1;29(3):640-645
pubmed: 29236940
Cell Cycle. 2019 Sep;18(18):2293-2306
pubmed: 31322047
Mol Cancer Ther. 2012 Oct;11(10):2138-48
pubmed: 22869556
J Cell Sci. 2012 Nov 15;125(Pt 22):5259-68
pubmed: 23377657
Drug Des Devel Ther. 2018 Feb 16;12:321-330
pubmed: 29497278
Cancer Res. 2017 May 1;77(9):2488-2499
pubmed: 28249908
Mol Cancer. 2017 Jan 30;16(1):8
pubmed: 28137272
J Hematol Oncol. 2017 Jun 19;10(1):123
pubmed: 28629371
Front Oncol. 2019 Jul 23;9:666
pubmed: 31396487
Oncogene. 2017 Apr 20;36(16):2255-2264
pubmed: 27748766
Cancer Cell. 2016 Aug 8;30(2):359-360
pubmed: 27505678
Neuro Oncol. 2012 Jul;14(7):870-81
pubmed: 22711607
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
Oncologist. 2016 Oct;21(10):1165-1175
pubmed: 27368881
Drug Resist Updat. 2018 Jul;39:1-17
pubmed: 30075834
Oncotarget. 2014 Aug 15;5(15):6512-25
pubmed: 25156567
Biosci Rep. 2016 Sep 16;36(5):
pubmed: 27402801
Curr Cancer Drug Targets. 2018;18(10):979-987
pubmed: 29237381
Nat Commun. 2015 Jan 06;6:5906
pubmed: 25562820
J Med Chem. 2014 Aug 28;57(16):6930-48
pubmed: 24831826
Int J Mol Sci. 2019 Feb 16;20(4):
pubmed: 30781465
Nat Cancer. 2020 Apr;1(4):382-393
pubmed: 32864625
Ann Oncol. 2021 Feb;32(2):208-217
pubmed: 33246021
Oncogene. 2006 Aug 28;25(38):5220-7
pubmed: 16936740
Lancet Oncol. 2018 Jul;19(7):904-915
pubmed: 29804902
Breast Care (Basel). 2017 Oct;12(5):304-308
pubmed: 29234249
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Nat Commun. 2019 Mar 26;10(1):1373
pubmed: 30914635
Cancer Discov. 2020 Jan;10(1):72-85
pubmed: 31594766
Lancet Oncol. 2015 Jan;16(1):25-35
pubmed: 25524798
Breast. 2018 Feb;37:126-133
pubmed: 29156384
Molecules. 2016 Jul 22;21(7):
pubmed: 27455225
Mol Cell. 2013 Apr 25;50(2):250-60
pubmed: 23622515
Clin Cancer Res. 2017 Aug 1;23(15):4055-4065
pubmed: 28270497
Cancer Discov. 2018 Nov;8(11):1390-1403
pubmed: 30206110
Lancet. 2020 Mar 7;395(10226):817-827
pubmed: 32145796
Clin Cancer Res. 2015 Nov 1;21(21):4947-59
pubmed: 25810375
Pharmacol Ther. 2017 Jul;175:91-106
pubmed: 28216025
Cell Cycle. 2014;13(24):3818-22
pubmed: 25483053
J Pathol. 2017 Jun;242(2):152-164
pubmed: 28349562
Curr Med Chem. 2009;16(14):1688-703
pubmed: 19442140
Oncotarget. 2017 Jul 18;8(29):47916-47930
pubmed: 28615518
Int J Mol Sci. 2020 Mar 16;21(6):
pubmed: 32188012
Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6289-93
pubmed: 7603984
Clin Cancer Res. 2017 Sep 1;23(17):5218-5224
pubmed: 28533223
Drug Resist Updat. 2018 Jan;36:47-76
pubmed: 29499837
Nature. 2015 Feb 12;518(7538):240-4
pubmed: 25409150
Oncologist. 2019 Dec;24(12):1514-1525
pubmed: 31217344
Cell. 2015 Sep 24;163(1):174-86
pubmed: 26406377
Oncol Lett. 2018 Jun;15(6):9216-9230
pubmed: 29844824
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Oncogene. 2008 Sep 11;27(40):5326-38
pubmed: 18504435
Curr Oncol Rep. 2020 May 16;22(6):57
pubmed: 32415339
Autophagy. 2014;10(12):2122-42
pubmed: 25427136
Cell Cycle. 2017 Aug 3;16(15):1453-1464
pubmed: 28678584
Nat Commun. 2017 Jun 27;8:15916
pubmed: 28653662
Drug Resist Updat. 2017 May;32:1-15
pubmed: 29145974
Mol Cancer Ther. 2018 May;17(5):908-920
pubmed: 29483206
Clin Cancer Res. 2013 Dec 15;19(24):6853-62
pubmed: 24141623
Cancer Cell. 2017 Dec 11;32(6):761-776.e6
pubmed: 29232554
Cancer Cell Int. 2020 Jun 17;20:253
pubmed: 32565737
Science. 2001 Oct 19;294(5542):502-3
pubmed: 11641478
Cancer Cell. 2003 Sep;4(3):160-2
pubmed: 14522248
Oncogene. 2020 Jun;39(25):4781-4797
pubmed: 32307447
J Clin Med. 2017 Dec 22;7(1):
pubmed: 29271928
Biosci Rep. 2019 Jul 23;39(7):
pubmed: 31278126
Oncogene. 2010 Jul 15;29(28):4018-32
pubmed: 20473330
Breast Cancer Res. 2020 Aug 12;22(1):87
pubmed: 32787886
Cancer Discov. 2018 Feb;8(2):216-233
pubmed: 29101163
Cancer Cell. 2014 Jul 14;26(1):136-49
pubmed: 25002028
BMC Cancer. 2011 Sep 28;11:417
pubmed: 21955753
Oncogene. 2001 Apr 30;20(19):2390-400
pubmed: 11402335
Cell. 2012 Jul 20;150(2):251-63
pubmed: 22817889
Cancer Prev Res (Phila). 2008 Jun;1(1):45-55
pubmed: 19138935
Nature. 2017 Aug 24;548(7668):471-475
pubmed: 28813415
Cell Cycle. 2012 Jul 15;11(14):2756-61
pubmed: 22767154
Mol Cell. 2015 Nov 19;60(4):547-60
pubmed: 26590714
Cancer Res. 2016 Apr 15;76(8):2301-13
pubmed: 27020857
Cancer Treat Rev. 2016 Apr;45:129-38
pubmed: 27017286
Mol Cancer Res. 2010 Oct;8(10):1375-87
pubmed: 20736297
Clin Cancer Res. 2017 Nov 15;23(22):6946-6957
pubmed: 28830923
Lung Cancer. 2020 Jul;145:216-218
pubmed: 32345450
Front Genet. 2020 Apr 15;11:349
pubmed: 32351542
Mol Cell Biol. 2015 May;35(9):1506-22
pubmed: 25733683
NPJ Breast Cancer. 2019 Jan 17;5:5
pubmed: 30675515
Oncotarget. 2016 Sep 13;7(42):68012-68022
pubmed: 27634906
Curr Oncol Rep. 2015 Feb;17(2):5
pubmed: 25677118
J Clin Oncol. 2018 Aug 20;36(24):2465-2472
pubmed: 29860922
Breast Cancer Res. 2016 Feb 09;18(1):17
pubmed: 26857361
Oncogene. 2003 Oct 2;22(43):6748-63
pubmed: 14555988
Expert Opin Pharmacother. 2018 Feb;19(3):299-305
pubmed: 29355400
PLoS One. 2019 Oct 25;14(10):e0223084
pubmed: 31652270
Mol Cancer Ther. 2012 Jul;11(7):1488-99
pubmed: 22564725
Int J Cancer. 2019 Sep 1;145(5):1179-1188
pubmed: 30478914